Doug Watson

Doug is currently a Director in Regulatory CMC Biologics at Merck, where he serves as regulatory CMC lead for an antibody drug conjugate program. Previously, Doug led a late-stage analytical team responsible for analytical strategies for commercialization of Merck’s biologics portfolio. In these roles, Doug has contributed to numerous pre-approval and post-approval biologics comparability studies. In his 10-year tenure at Merck, Doug has been privileged to serve in roles encompassing development, commercialization, and post-approval manufacturing support for small and large molecules. Doug’s educational background includes a B.S. in Biomedical Engineering from the University of Virginia and a Ph.D. in Bioengineering from the University of California at Berkeley and San Francisco. Outside of work, Doug cherishes every moment with his wife, two daughters, and extended family.